PMID- 34008897
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1365-2184 (Electronic)
IS  - 0960-7722 (Print)
IS  - 0960-7722 (Linking)
VI  - 54
IP  - 7
DP  - 2021 Jul
TI  - Naringin-inlaid silk fibroin/hydroxyapatite scaffold enhances human umbilical 
      cord-derived mesenchymal stem cell-based bone regeneration.
PG  - e13043
LID - 10.1111/cpr.13043 [doi]
LID - e13043
AB  - OBJECTIVES: Large bone defects are a common, debilitating clinical condition that 
      have substantial global health and economic burden. Bone tissue engineering 
      technology has become one of the most promising approaches for regenerating 
      defective bones. In this study, we fabricated a naringin-inlaid composite silk 
      fibroin/hydroxyapatite (NG/SF/HAp) scaffold to repair bone defects. MATERIALS AND 
      METHODS: The salt-leaching technology was used to fabricate the NG/SF/HAp 
      scaffold. The cytocompatibility of the NG/SF/HAp scaffold was assessed using 
      scanning electron microscopy, live/dead cell staining and phalloidin staining. 
      The osteogenic and angiogenic properties were assessed in vitro and in vivo. 
      RESULTS: The porous NG/SF/HAp scaffold had a well-designed biomimetic porous 
      structure with osteoinductive and angiogenic activities. A gene microarray 
      identified 854 differentially expressed genes between human umbilical 
      cord-derived mesenchymal stem cells (hUCMSCs) cultured on SF-nHAp scaffolds and 
      cells cultured on NG/SF/HAp scaffolds. The underlying osteoblastic mechanism was 
      investigated using hUCMSCs in vitro. Naringin facilitated hUCMSC ingrowth into 
      the SF/HAp scaffold and promoted osteogenic differentiation. The osteogenic and 
      angiogenic capabilities of cells cultured in the NG/SF/HAp scaffold were superior 
      to those of cells cultured in the SF/HAp scaffold. CONCLUSIONS: The data indicate 
      the potential of the SF/HAp composite scaffold incorporating naringin for bone 
      regeneration.
CI  - (c) 2021 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.
FAU - Zhao, Zhi-Hu
AU  - Zhao ZH
AUID- ORCID: 0000-0001-7081-8914
AD  - Department of Orthopaedics, Tianjin Hospital, Tianjin, China.
FAU - Ma, Xin-Long
AU  - Ma XL
AD  - Department of Orthopaedics, Tianjin Hospital, Tianjin, China.
FAU - Zhao, Bin
AU  - Zhao B
AD  - Department of Orthopaedics, Tianjin Hospital, Tianjin, China.
FAU - Tian, Peng
AU  - Tian P
AD  - Department of Orthopaedics, Tianjin Hospital, Tianjin, China.
FAU - Ma, Jian-Xiong
AU  - Ma JX
AD  - Tianjin Institute of Orthopedics in Traditional Chinese and Western Medicine, 
      Tianjin, China.
FAU - Kang, Jia-Yu
AU  - Kang JY
AD  - Department of Orthopedics, Jinhua Municipal Central Hospital, Jinhua, Zhejiang 
      Province, China.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Tianjin Institute of Orthopedics in Traditional Chinese and Western Medicine, 
      Tianjin, China.
FAU - Guo, Yue
AU  - Guo Y
AD  - Tianjin Institute of Orthopedics in Traditional Chinese and Western Medicine, 
      Tianjin, China.
FAU - Sun, Lei
AU  - Sun L
AD  - Tianjin Institute of Orthopedics in Traditional Chinese and Western Medicine, 
      Tianjin, China.
LA  - eng
GR  - 81871777/National Natural Science Foundation of China/
GR  - 81572154/National Natural Science Foundation of China/
GR  - 81501061/National Natural Science Foundation of China/
GR  - 81401792/National Natural Science Foundation of China/
GR  - TJYY2117/Technology Fund of Tianjin Hospital/
GR  - ZC20068/Natural Science Foundation of Tianjin/
GR  - 81401792. Technology Fund of Tianjin Hospital (TJYY2117) and Natural Science 
      Foundation of Tianjin (ZC20068)./National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20210519
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
RN  - 0 (Biocompatible Materials)
RN  - 0 (Flavanones)
RN  - 9007-76-5 (Fibroins)
RN  - 91D9GV0Z28 (Durapatite)
RN  - N7TD9J649B (naringin)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials/chemistry/pharmacology
MH  - *Bone Regeneration
MH  - Bone and Bones/pathology
MH  - Cell Differentiation/drug effects
MH  - Durapatite/*chemistry
MH  - Fibroins/*chemistry
MH  - Flavanones/*chemistry
MH  - Humans
MH  - Kidney/drug effects/pathology
MH  - Liver/drug effects/pathology
MH  - Male
MH  - Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/cytology/metabolism
MH  - Osteogenesis/drug effects
MH  - Porosity
MH  - Rabbits
MH  - Tissue Engineering
MH  - Tissue Scaffolds/*chemistry
MH  - Umbilical Cord/cytology
PMC - PMC8249788
OTO - NOTNLM
OT  - Naringin
OT  - bone defect
OT  - hydroxyapatite
OT  - silk fibroin
COIS- None.
EDAT- 2021/05/20 06:00
MHDA- 2021/07/13 06:00
PMCR- 2021/05/19
CRDT- 2021/05/19 09:07
PHST- 2021/03/17 00:00 [revised]
PHST- 2021/01/06 00:00 [received]
PHST- 2021/04/03 00:00 [accepted]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2021/05/19 09:07 [entrez]
PHST- 2021/05/19 00:00 [pmc-release]
AID - CPR13043 [pii]
AID - 10.1111/cpr.13043 [doi]
PST - ppublish
SO  - Cell Prolif. 2021 Jul;54(7):e13043. doi: 10.1111/cpr.13043. Epub 2021 May 19.